Livzon Pharmaceutical Group (01513.HK) jumped nearly 6% during Tuesday's trading session, with shares climbing 5.96% to HK$34.65 by press time. Trading volume reached HK$41.87 million amid heightened investor interest. The catalyst emerged from the company's official WeChat announcement confirming completion of patient enrollment for Phase II clinical trials of its cardiovascular breakthrough drug H001.
This novel oral inhibitor directly targets thrombin (Factor IIa) – the final coagulation pathway – positioning it as a promising prophylactic against venous thromboembolism following major orthopedic surgeries. H001 distinguishes itself through rapid onset kinetics, enhanced safety margins, and convenient dosing protocols. Currently, no medications sharing its mechanism have reached the Chinese market, potentially establishing H001 as a pioneering therapeutic alternative.
The Phase II study specifically examines patients undergoing total knee arthroplasty (TKA). Primary objectives include evaluating multiple dosage regimens for postoperative VTE prevention efficacy while comprehensively assessing safety parameters. Researchers will additionally analyze pharmacokinetic and pharmacodynamic profiles of active metabolite Rn-001, aiming to establish scientific foundations for precision dosing strategies. This milestone accelerates the drug's development timeline in China's cardiovascular therapeutics landscape.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。